PASSing to the patient side: early achieving of an acceptable symptom state in patients with rheumatoid arthritis treated with Janus kinase inhibitors

被引:0
作者
Garufi, Cristina [1 ]
Mancuso, Silvia [1 ]
Ceccarelli, Fulvia [1 ]
Caruso, Letizia [1 ]
Alessandri, Cristiano [1 ]
Di Franco, Manuela [1 ]
Priori, Roberta [2 ]
Riccieri, Valeria [1 ]
Scrivo, Rossana [1 ]
Truglia, Simona [1 ,3 ]
Conti, Fabrizio [1 ]
Spinelli, Francesca Romana [1 ]
机构
[1] Sapienza Univ Rome, Dept Clin Internal Anesthesiol & Cardiovasc Sci Rh, Rome, Italy
[2] UniCamillus Int Med Univ Rome, Rome, Italy
[3] AOU Policlin Umberto I, Rheumatol, Rome, Italy
关键词
rheumatoid arthritis; JAK inhibitors; patients acceptable symptom state; pain; quality of life; CLINICALLY IMPORTANT IMPROVEMENT; DISEASE-ACTIVITY; GLOBAL ASSESSMENT; CUTOFF POINTS; BARICITINIB; RA; METHOTREXATE; TOFACITINIB; CRITERIA; PHASE-3;
D O I
10.4081/reumatismo.2024.1725
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Patients Acceptable Symptom State (PASS) is a single dichotomized question assessing health satisfaction. We aimed to investigate PASS achievement within 4 weeks of treatment with Janus kinase (JAK) inhibitors (Jakinibs) and its association with treatment response after 4 and 12 weeks in rheumatoid arthritis (RA) patients. Methods. We recruited consecutive RA patients starting baricitinib or tofacitinib. At baseline, 4 and 12 weeks, we calculated disease activity [Disease Activity Score on 28 joints (DAS28), Clinical Disease Activity Index, Simplified Disease Activity Index], disease status [remission and low-disease activity (LDA)], percentage of patients achieving PASS, and the time to attain PASS. We assessed the impact of clinically relevant variables on PASS achievement by logistic regression analysis. Results. We enrolled 113 patients [98 (86.7%) females; median age 59.6 (interquartile range 16.9), median disease duration 144 (132) months]. 90 (79.6%) patients achieved PASS after 10 (8) days. A similar percentage of PASS achievers and non-achievers was in remission/LDA at weeks 4 and 12, but the reduction of disease activity was significantly greater in PASS achievers. All patients achieving Boolean remission at weeks 4 and 12 had achieved PASS within 4 weeks. The impact of Patients Global Assessment (PGA) on DAS28 was significantly greater in PASS non-achievers compared to PASS achievers; inversely, the impact of C-reactive protein was more relevant in PASS achievers. At multivariate analysis, pain and PGA were significantly associated with PASS. Conclusions. In our cohort, Jakinibs allowed an early achievement of PASS in a great percentage of RA patients. PASS is strictly dependent on PGA and pain and could suggest, early in the management of RA patients, therapeutic success.
引用
收藏
页数:8
相关论文
共 37 条
  • [1] The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review
    Almutairi, Khalid
    Nossent, Johannes
    Preen, David
    Keen, Helen
    Inderjeeth, Charles
    [J]. RHEUMATOLOGY INTERNATIONAL, 2021, 41 (05) : 863 - 877
  • [2] Baricitinib retention rate: 'real-life' data from a mono-centric cohort of patients affected by rheumatoid arthritis
    Baldi, Caterina
    Berlengiero, Virginia
    Falsetti, Paolo
    Cartocci, Alessandra
    Conticini, Edoardo
    D'Alessandro, Roberto
    D'Ignazio, Emilio
    Bardelli, Marco
    Fabbroni, Marta
    Cantarini, Luca
    Frediani, Bruno
    Gentileschi, Stefano
    [J]. FRONTIERS IN MEDICINE, 2023, 10
  • [3] Benaglio F, 2021, CLIN EXP RHEUMATOL, V39, P1077, DOI 10.55563/clinexprheumatol/8uy6vj
  • [4] Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia
    Bird, Paul
    Littlejohn, Geoffrey
    Butcher, Belinda
    Smith, Tegan
    Pereira, Candida da Fonseca
    Witcombe, David
    Griffiths, Hedley
    [J]. CLINICAL RHEUMATOLOGY, 2020, 39 (09) : 2545 - 2551
  • [5] High patient global assessment scores in patients with rheumatoid arthritis otherwise in remission do not reflect subclinical inflammation
    Brites, Luisa
    Rovisco, Joao
    Costa, Flavio
    de Freitas, Joao Pedro Dinis
    Jesus, Diogo
    Eugenio, Gisela
    Serra, Sara
    Duarte, Catia
    Ferreira, Ricardo J. O.
    da da Silva, Jose Antonio Pereira
    [J]. JOINT BONE SPINE, 2021, 88 (06)
  • [6] Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis
    Bugatti, Serena
    De Stefano, Ludovico
    D'Onofrio, Bernardo
    Nicrosini, Andrea
    Mauric, Eleonora
    di Lernia, Michele
    Sakellariou, Garifallia
    Favalli, Ennio Giulio
    Manzo, Antonio
    Caporali, Roberto
    Montecucco, Carlomaurizio
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (09) : 1206 - 1213
  • [7] Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
    Burmester, Gerd R.
    Blanco, Ricardo
    Charles-Schoeman, Christina
    Wollenhaupt, Juergen
    Zerbini, Cristiano
    Benda, Birgitta
    Gruben, David
    Wallenstein, Gene
    Krishnaswami, Sriram
    Zwillich, Samuel H.
    Koncz, Tamas
    Soma, Koshika
    Bradley, John
    Mebus, Charles
    [J]. LANCET, 2013, 381 (9865) : 451 - 460
  • [8] Evaluation of the Patient Acceptable Symptom State (PASS) in Italian Patients Affected by Systemic Lupus Erythematosus: Association with Disease Activity Indices
    Conti, Fabrizio
    Ceccarelli, Fulvia
    Massaro, Laura
    Pacucci, Viviana A.
    Miranda, Francesca
    Truglia, Simona
    Cipriano, Enrica
    Martinelli, Francesco
    Leccese, Ilaria
    Spinelli, Francesca Romana
    Alessandri, Cristiano
    Perricone, Carlo
    Valesini, Guido
    [J]. PLOS ONE, 2013, 8 (09):
  • [9] Crispino N, 2021, CLIN EXP RHEUMATOL, V39, P668, DOI 10.55563/clinexprheumatol/e7ayu8
  • [10] ToRaRI (Tofacitinib in Rheumatoid Arthritis a Real-Life experience in Italy): Effectiveness, safety profile of tofacitinib and concordance between patient-reported outcomes and physician's global assessment of disease activity in a retrospective study in Central-Italy
    D'Alessandro, Francesco
    Cazzato, Massimiliano
    Laurino, Elenia
    Morganti, Riccardo
    Bardelli, Marco
    Frediani, Bruno
    Buongarzone, Claudia
    Moroncini, Gianluca
    Guiducci, Serena
    Cometi, Laura
    Benucci, Maurizio
    Ligobbi, Francesca
    Marotto, Daniela
    Mosca, Marta
    [J]. CLINICAL RHEUMATOLOGY, 2024, 43 (02) : 657 - 665